https://orcid.org/0000-0002-8051-3185
References
- Rocha P, Hardy-Werbin M, Naranjo D, et al. CD103 + CD8+ lymphocytes characterize the immune infiltration in a case with pseudoprogression in squamous NSCLC. J Thorac Oncol. 2018;13(10):e193–e196.
- Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385–396.
- Seymour L, Bogaerts J, Perrone A, RECIST working group, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152.
- Hodi FS, Hwu W-J, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510–1517.
- Tanizaki J, Hayashi H, Kimura M, et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer. 2016;102:44–48.
- Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer. 2016;4:80
- Cohen JV, Alomari AK, Vortmeyer AO, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res. 2016;4(3):179–182.
- Kim HK, Baek S-W, Jeong Y, et al. Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report. Mol Clin Oncol. 2019;11(2):132–134.
- Suyanto S, Yeo D, Khan S. A rare delayed atypical pseudoprogression in nivolumab-treated non-small-cell lung cancer. Case Rep Oncol Med. 2019;2019:8356148
- Kumagai T, Kimura M, Inoue T, et al. Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. Thorac Cancer. 2017;8(3):275–277.
- Wong AS, Thian Y-L, Kapur J, et al. Pushing the limits of immune-related response: a case of “extreme pseudoprogression". Cancer Immunol Immunother. 2018;67(7):1105–1111.
- Hochmair MJ, Schwab S, Burghuber OC, et al. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer. 2017;113:4–6.
- Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16(4):655–670.